While the utility of PD1/PD-L1 inhibition in most T-cell lymphomas appears underwhelming so far, the PD-1 inhibitors have been demonstrated to be highly effective at salvaging relapsed or refractory NK/T-cell lymphoma. This evidence concerns the gene CD274 and T-cell non-Hodgkin lymphoma.